Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site...
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net...
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Jan. 8, 2025 /PRNewswire/ -- Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough results;...
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug research, development and manufacturing services, this...
